-+ 0.00%
-+ 0.00%
-+ 0.00%

GBC AG reiterates Novogenia buy, cuts price target to EUR 20.00

PUBT·10/08/2026 08:31:42
Listen to the news
GBC AG reiterates Novogenia buy, cuts price target to EUR 20.00
  • GBC set a “buy” rating on Novogenia, cutting its price target to EUR 20 from EUR 24.75.
  • H1 2026 revenue fell 7.1% to EUR 25.66 million; trading segment sales dropped 14.6% to about EUR 19.9 million.
  • Core DNA-analysis business grew about 20% to roughly EUR 5.8 million, helping lift EBIT to a loss of EUR 4.68 million.
  • GBC cut its 2026 revenue forecast to EUR 56.51 million; it sees 2026 EBIT at a loss of EUR 5.15 million.
  • GBC kept its 2027 forecast at EUR 70.95 million revenue, projecting EBIT of EUR 1.26 million, implying a move past break-even.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novogenia AG published the original content used to generate this news brief via EQS News (Ref. ID: rc_27038) on October 08, 2026, and is solely responsible for the information contained therein.